| 摘要 |
This disclosure relates to methods administering various compounds in conjunction with dextromethorphan to a human being. Dosage forms, drug delivery systems, and methods related to dextromethorphan or dextrorphan and bupropion, hydroxybupropion, erythrohydroxybupropion, threohydroxybupropion, or a metabolite or prodrug of any of these compounds are also disclosed |
| 主权项 |
1. A method of extending dextromethorphan plasma levels in a human being that is an extensive metabolizer of dextromethorphan and is in need of treatment with dextromethorphan, comprising co-administering: 1) a hydroxybupropion, a threohydroxybupropion, an erythrohydroxybupropion, or a bupropion with 2) a dextromethorphan, to the human being for at least eight consecutive days, wherein the daily dose of the dextromethorphan is about 15 mg to about 300 mg, and co-administering the hydroxybupropion, the threohydroxybupropion, the erythrohydroxybupropion, or the bupropion with the dextromethorphan results in a Cavg of the dextromethorphan that, on the eighth day, is at least about 20 times the Cavg that would be achieved by administering the same amount of the dextromethorphan without the hydroxybupropion, the threohydroxybupropion, the erythrohydroxybupropion, or the bupropion for eight consecutive days. |
